Abstract
During the past several years, targeted therapies have significantly improved outcomes in advanced basal cell carcinoma, psoriasis, and metastatic melanoma. This article reviews how advances in our understanding of the molecular pathogenesis of these diseases led to the development of targeted therapies and how these therapies are improving outcomes. Research is ongoing to address continuing challenges of drug resistance, adverse effects, and how best to use the new medications.
Copyright © 2015 Cleveland Clinic.
MeSH terms
-
Adult
-
Anilides / therapeutic use
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Agents / therapeutic use*
-
Azetidines / therapeutic use
-
Brain Neoplasms / drug therapy*
-
Brain Neoplasms / genetics
-
Brain Neoplasms / secondary
-
Carcinoma, Basal Cell / drug therapy*
-
Carcinoma, Basal Cell / pathology
-
Dermatologic Agents / therapeutic use*
-
Dermatology
-
Etanercept / therapeutic use
-
Female
-
Humans
-
Imidazoles / therapeutic use
-
Indoles / therapeutic use
-
Interleukin-17 / antagonists & inhibitors
-
Male
-
Melanoma / drug therapy*
-
Melanoma / genetics
-
Melanoma / secondary
-
Middle Aged
-
Molecular Targeted Therapy
-
Oximes / therapeutic use
-
Piperidines / therapeutic use
-
Proto-Oncogene Proteins B-raf / genetics
-
Psoriasis / drug therapy*
-
Pyridines / therapeutic use
-
Pyridones / therapeutic use
-
Pyrimidinones / therapeutic use
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / genetics
-
Skin Neoplasms / pathology
-
Sulfonamides / therapeutic use
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Ustekinumab / therapeutic use
-
Vemurafenib
Substances
-
Anilides
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Azetidines
-
Dermatologic Agents
-
HhAntag691
-
Imidazoles
-
Indoles
-
Interleukin-17
-
Oximes
-
Piperidines
-
Pyridines
-
Pyridones
-
Pyrimidinones
-
Sulfonamides
-
Tumor Necrosis Factor-alpha
-
Vemurafenib
-
trametinib
-
brodalumab
-
ixekizumab
-
secukinumab
-
Proto-Oncogene Proteins B-raf
-
cobimetinib
-
Ustekinumab
-
Etanercept
-
dabrafenib